Skip to main content

Lund University Publications

LUND UNIVERSITY LIBRARIES

Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial

Jungnelius, U ; Ringborg, U ; Aamdal, S ; Mattsson, J ; Stierner, U ; Ingvar, C LU ; Malmström, P LU ; Andersson, R ; Karlsson, M and Willman, K , et al. (1998) In European Journal of Cancer 34(9). p.1368-1374
Abstract

In a multicentre phase III study of disseminated malignant melanoma performed in Sweden and Norway, 326 patients were randomised to receive treatment with the combination dacarbazine [DTIC] (D) and vindesine (V) with or without the addition of cisplatin (P). D was given intravenously (i.v.) at a dose of 250 mg/m2 days 1-5 every 4 weeks and V was given i.v. at a dose of 3.0 mg/m2 day 1 weekly. P was given i.v. at a dose of 100 mg/m2 day 1 every 4 weeks. There was no statistically significant difference in overall survival between the treatment arms (P = 0.22). Increased toxicity was observed in the treatment arm containing P of which leucopenia, alopecia and nausea/vomiting were the most pronounced. The median time to progression was... (More)

In a multicentre phase III study of disseminated malignant melanoma performed in Sweden and Norway, 326 patients were randomised to receive treatment with the combination dacarbazine [DTIC] (D) and vindesine (V) with or without the addition of cisplatin (P). D was given intravenously (i.v.) at a dose of 250 mg/m2 days 1-5 every 4 weeks and V was given i.v. at a dose of 3.0 mg/m2 day 1 weekly. P was given i.v. at a dose of 100 mg/m2 day 1 every 4 weeks. There was no statistically significant difference in overall survival between the treatment arms (P = 0.22). Increased toxicity was observed in the treatment arm containing P of which leucopenia, alopecia and nausea/vomiting were the most pronounced. The median time to progression was significantly longer in patients treated with DVP (4.2 versus 2.2 months, P = 0.007). In conclusion, adding P to DV did not change overall survival but did significantly increase toxicity.

(Less)
Please use this url to cite or link to this publication:
author
; ; ; ; ; ; ; ; and , et al. (More)
; ; ; ; ; ; ; ; ; ; ; and (Less)
publishing date
type
Contribution to journal
publication status
published
keywords
Adolescent, Adult, Aged, Antineoplastic Combined Chemotherapy Protocols/adverse effects, Cisplatin/administration & dosage, Dacarbazine/administration & dosage, Female, Hematologic Diseases/chemically induced, Humans, Lung Neoplasms/secondary, Male, Melanoma/drug therapy, Middle Aged, Nausea/chemically induced, Prospective Studies, Regression Analysis, Skin Neoplasms/drug therapy, Survival Analysis, Treatment Outcome, Vindesine/administration & dosage, Vomiting/chemically induced
in
European Journal of Cancer
volume
34
issue
9
pages
1368 - 1374
publisher
Elsevier
external identifiers
  • scopus:17344382437
  • pmid:9849419
ISSN
0959-8049
DOI
10.1016/s0959-8049(98)00068-9
language
English
LU publication?
no
id
b0b47a66-baa5-4015-ad7f-b51aa7ec59aa
date added to LUP
2022-03-01 12:48:02
date last changed
2024-01-07 23:30:28
@article{b0b47a66-baa5-4015-ad7f-b51aa7ec59aa,
  abstract     = {{<p>In a multicentre phase III study of disseminated malignant melanoma performed in Sweden and Norway, 326 patients were randomised to receive treatment with the combination dacarbazine [DTIC] (D) and vindesine (V) with or without the addition of cisplatin (P). D was given intravenously (i.v.) at a dose of 250 mg/m2 days 1-5 every 4 weeks and V was given i.v. at a dose of 3.0 mg/m2 day 1 weekly. P was given i.v. at a dose of 100 mg/m2 day 1 every 4 weeks. There was no statistically significant difference in overall survival between the treatment arms (P = 0.22). Increased toxicity was observed in the treatment arm containing P of which leucopenia, alopecia and nausea/vomiting were the most pronounced. The median time to progression was significantly longer in patients treated with DVP (4.2 versus 2.2 months, P = 0.007). In conclusion, adding P to DV did not change overall survival but did significantly increase toxicity.</p>}},
  author       = {{Jungnelius, U and Ringborg, U and Aamdal, S and Mattsson, J and Stierner, U and Ingvar, C and Malmström, P and Andersson, R and Karlsson, M and Willman, K and Wist, E and Bjelkengren, G and Westberg, R}},
  issn         = {{0959-8049}},
  keywords     = {{Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols/adverse effects; Cisplatin/administration & dosage; Dacarbazine/administration & dosage; Female; Hematologic Diseases/chemically induced; Humans; Lung Neoplasms/secondary; Male; Melanoma/drug therapy; Middle Aged; Nausea/chemically induced; Prospective Studies; Regression Analysis; Skin Neoplasms/drug therapy; Survival Analysis; Treatment Outcome; Vindesine/administration & dosage; Vomiting/chemically induced}},
  language     = {{eng}},
  number       = {{9}},
  pages        = {{1368--1374}},
  publisher    = {{Elsevier}},
  series       = {{European Journal of Cancer}},
  title        = {{Dacarbazine-vindesine versus dacarbazine-vindesine-cisplatin in disseminated malignant melanoma. A randomised phase III trial}},
  url          = {{http://dx.doi.org/10.1016/s0959-8049(98)00068-9}},
  doi          = {{10.1016/s0959-8049(98)00068-9}},
  volume       = {{34}},
  year         = {{1998}},
}